| 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- | | 阿里巴巴-W(09988) | 30.85 亿元 | +6.95 亿元 | | 中芯国际(00981) | 19.39 亿元 | -7432.54 万元 | | 中兴通讯(00763) | 18.71 亿元 | -1.84 亿元 | | 长飞光纤光缆(06869) | 16.07 亿元 | -1.55 亿元 | | 腾讯控股(00700) | 13.10 亿元 | +3.00 亿元 | | 小米集团-W(01810) | 12.65 亿元 | -3.21 亿元 | | 农业银行(01288) | 11.52 亿元 | +3.49 亿元 | | 建设银行(00939) | 8.94 亿元 | -1.96 亿元 | | 工商银行(01398) | 7.96 亿元 | -7978.89 万元 | | 中国海洋石油(00883) | 7.52 亿元 | -5.18 亿元 | 深港通（南向）十大活跃成交公司 | 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- | | 阿里巴巴-W(09988) | 3 ...

Core Viewpoint - The article discusses the strategic market operations of Haixi New Drug (02637) over the past two months, highlighting a well-planned effort to increase market capitalization and liquidity in preparation for inclusion in the Hong Kong Stock Connect program [1][3]. Group 1: Market Operation Phases - The market operation can be divided into four distinct phases aimed at enhancing and stabilizing market capitalization to meet the Hong Kong Stock Connect inclusion criteria [3]. Phase 1: Accumulation - From October 20 to October 30, the stock price rose from 97.50, increasing by 18.63% over eight trading days, with a significant trading volume of 379.17 million and a turnover rate of 4.82% [4][5]. - The bullish trading volume accounted for 87.5%, indicating strong buying power and establishing a solid foundation for future operations [4]. Phase 2: Technical Adjustment - From October 31 to November 5, the stock experienced a technical adjustment with a price decline of 5.79% and a drastic drop in trading volume to 47.87 million, reflecting a controlled "volume reduction" strategy to clear short-term floating positions [5][6]. Phase 3: Breakthrough - From November 6 to November 12, the stock surged from 112.50 to 147.00, marking a 26.49% increase with a low turnover rate of 0.79%, indicating a high level of control by the main operators [7][8]. Phase 4: Consolidation - From November 13 to December 9, the stock price stabilized around 130.54, showing strong support with more bullish days than bearish ones, preparing for further market consensus and potential value expansion [9][10]. Group 2: Market Capitalization Strategy - Haixi New Drug has submitted an application for "full circulation" of shares, which will allow major shareholders to trade their shares in the secondary market after a 12-month lock-up period, enhancing the motivation for active market capitalization management [12]. - The company aims to exceed the core requirement of a daily average market capitalization of 93 billion HKD to qualify for the Hong Kong Stock Connect, achieving a market cap of 97.7 billion HKD as of December 10 [12][13]. - The strategy is designed to secure a "market capitalization safety cushion" by significantly increasing the market cap early in the assessment period, thus reducing the risk of falling below the required threshold [12][13].

南向资金今日成交概况 12月10日南向资金全天成交额862.35亿港元，成交净卖出10.19亿港元。 证券时报·数据宝统计显示，12月10日恒生指数上涨0.42%，南向资金合计买入成交426.08亿港元，卖出 成交436.27亿港元，合计成交额862.35亿港元。 具体看，港股通（沪）买入成交239.96亿港元，卖出成交272.17亿港元，合计成交额512.13亿港元，成 交净卖出32.21亿港元；港股通（深）买入成交186.12亿港元，卖出成交164.10亿港元，合计成交350.22 亿港元，成交净买入22.02亿港元。（数据宝） | | 买入成交额（亿港元） | 卖出成交额（亿港元） | 成交净买入（亿港元） | | --- | --- | --- | --- | | 港股通（深） | 186.12 | 164.10 | 22.02 | | 港股通（沪） | 239.96 | 272.17 | -32.21 | | 合计 | 426.08 | 436.27 | -10.19 | （文章来源：证券时报网） ...

Core Viewpoint - The stock price of XinTai Medical (02291) has been on a downward trend since August 26, following a significant share reduction by its major shareholder, Lepu Medical, which has led to decreased investor confidence and trading volume [1][2][4]. Group 1: Stock Performance - On November 19, XinTai Medical's stock price hit a low of HKD 17.95, marking the first time it fell below HKD 18 since a 49.26% increase on April 22 [1]. - The stock closed at HKD 17.20 on December 8, nearing its recent low of HKD 17.01 [1]. - The downward trend began after the major shareholder's announcement on August 26, which caused an immediate sell-off, leading to a 12.75% drop on that day [3]. Group 2: Shareholder Actions - On August 26, Lepu Medical announced the sale of 11.14 million shares at HKD 22.79 each, representing 3.21% of XinTai Medical's total issued shares [2]. - Despite the announcement claiming confidence in the company's operations, the immediate market reaction was negative, with significant sell-offs and a subsequent decline in trading volume [4]. Group 3: Market Dynamics - Following the announcement, trading volume dropped significantly, with daily averages falling below 1 million shares, indicating a lack of confidence among investors [4]. - The stock's performance has raised concerns about XinTai Medical's status in the Hong Kong Stock Connect, with an average market capitalization of HKD 68.85 billion, just above the HKD 60.71 billion threshold [6]. Group 4: Industry Context - A nationwide procurement initiative for structural heart disease occluders has been initiated, which could impact pricing and market dynamics for XinTai Medical's products [9][10]. - The market for heart occluders is projected to exceed HKD 60 billion by 2025, with significant growth expected [10]. - XinTai Medical's revenue from congenital heart disease occluders was HKD 161 million in the first half of the year, accounting for 48.7% of total revenue, indicating its importance to the company's financial health [11].

Core Viewpoint - The Hang Seng Index fell by 1.23% on December 8, with southbound capital recording a total transaction amount of HKD 943.11 billion, resulting in a net inflow of HKD 15.40 billion [1] Group 1: Southbound Capital Transactions - Total southbound capital transactions amounted to HKD 943.11 billion, with buy transactions at HKD 479.25 billion and sell transactions at HKD 463.85 billion, leading to a net buy of HKD 15.40 billion [1] - The Shenzhen Stock Connect recorded a total transaction amount of HKD 381.14 billion, with net buying of HKD 4.32 billion, while the Shanghai Stock Connect had a total transaction amount of HKD 561.97 billion with net buying of HKD 11.08 billion [1] Group 2: Active Stocks - Alibaba-W had the highest transaction amount among southbound stocks at HKD 71.47 billion, followed by Xiaomi Group-W at HKD 49.42 billion and SMIC at HKD 45.85 billion [1] - Xiaomi Group-W led in net buying with HKD 11.73 billion, while Tencent Holdings saw the highest net selling at HKD 7.62 billion [1][2] Group 3: Continuous Net Buying and Selling - Three stocks experienced continuous net buying for over three days, with Xiaomi Group-W leading at 7 days and a total net buy of HKD 62.39 billion [2] - Tencent Holdings and Alibaba-W were among the stocks with the highest continuous net selling, totaling HKD 46.68 billion and HKD 18.81 billion respectively [2]

Core Viewpoint - The Tianhong CSI Hong Kong Stock Connect Central State-Owned Enterprises Dividend ETF (159281) experienced a closing drop of 0.77% on December 8, with a trading volume of 34.4572 million yuan [1]. Group 1: Fund Overview - The Tianhong CSI Hong Kong Stock Connect Central State-Owned Enterprises Dividend ETF was established on August 20, 2025, with an annual management fee of 0.50% and a custody fee of 0.10% [1]. - As of December 5, the fund had a total of 304 million shares and a total size of 316 million yuan [1]. - The fund's performance benchmark is the adjusted return of the CSI Hong Kong Stock Connect Central State-Owned Enterprises Dividend Index [1]. Group 2: Liquidity and Performance - Over the past 20 trading days, the fund's cumulative trading amount reached 799 million yuan, with an average daily trading amount of 39.9361 million yuan [1]. - The current fund manager, He Yuxuan, has managed the fund since its inception, achieving a return of 4.01% during the management period [1]. Group 3: Top Holdings - The fund's top holdings include: - COSCO Shipping Holdings (0.85% holding, 218,000 shares, market value of 2.9175 million yuan) - Orient Overseas International (0.40% holding, 10,500 shares, market value of 1.3717 million yuan) - China Foreign Transport (0.33% holding, 270,000 shares, market value of 1.1396 million yuan) - China National Petroleum (0.32% holding, 162,000 shares, market value of 1.0973 million yuan) - CITIC Bank (0.32% holding, 175,000 shares, market value of 1.1136 million yuan) [2]. - Other significant holdings include China National Offshore Oil (0.29%), China Shenhua Energy (0.29%), China People's Insurance Group (0.29%), China Unicom (0.28%), and Agricultural Bank of China (0.27%) [2].

Core Viewpoint - Silver诺医药-B (02591) has seen its stock price increase by over 5%, marking three consecutive days of gains, currently trading at 43.42 HKD with a transaction volume of 7.6433 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B has risen by 5.03% [1] - The current trading price is 43.42 HKD [1] - The transaction volume reached 764.33 million HKD [1] Group 2: Market Inclusion - Silver诺医药 has been included in the Hang Seng Composite Index as part of the quarterly review results [1] - The change will take effect on December 8, 2025 [1] Group 3: Company Overview - Silver诺医药 is focused on the field of metabolic diseases [1] - The company has multiple innovative drug development pipelines targeting diabetes, obesity, and non-alcoholic fatty liver disease [1] - All drugs are self-developed and possess global intellectual property rights, with a comprehensive global research and market layout [1]

Core Viewpoint - Silver诺医药-B (02591) has seen a stock price increase of over 5%, marking three consecutive days of gains, currently trading at 43.42 HKD with a transaction volume of 7.6433 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B has risen by 5.03% [1] - The current trading price is 43.42 HKD [1] - The trading volume reached 7.6433 million HKD [1] Group 2: Index Inclusion - Silver诺医药 has been included in the Hang Seng Composite Index, with changes effective from December 8, 2025 [1] - This inclusion is part of the quarterly review results of the Hang Seng Index series [1] Group 3: Company Overview - Silver诺医药 is focused on the field of metabolic diseases [1] - The company has multiple innovative drug development pipelines targeting diabetes, obesity, and non-alcoholic fatty liver disease, all of which are self-developed [1] - The company holds global intellectual property rights and has a comprehensive global research and market layout [1]

Group 1: Top Net Buy/Sell Companies - Alibaba-W (9988.HK) had a net buy amount of 13.054 billion CNY, with a holding change of 86,161,822 shares[8] - WanGuo Gold Group (2979.HK) saw a net buy of 3.994 billion CNY, with a holding change of 501,802,800 shares[8] - Kuaishou-W (1024.HK) recorded a net buy of 2.185 billion CNY, with a holding change of 32,228,490 shares[8] - SMIC (0981.HK) was the top net sell company with a net sell amount of -1.720 billion CNY, with a holding change of -24,994,033 shares[9] - Huahong Semiconductor (1347.HK) had a net sell of -726 million CNY, with a holding change of -9,743,244 shares[9] Group 2: Industry Distribution of Net Buy/Sell - Financial sector had a net buy of 1.843 billion CNY, indicating strong investor interest[13] - Energy sector recorded a net sell of -9.89 billion CNY, reflecting a decrease in investor confidence[13] - Information Technology sector had a net buy of 1.85 billion CNY, showing continued investment in tech companies[13] Group 3: Active Stocks - Alibaba-W (9988.HK) was the most active stock with a total trading volume of 44.08 billion CNY and a net buy of 8.00 billion CNY on November 28[18] - Tencent Holdings (0700.HK) had a trading volume of 15.28 billion CNY with a net sell of -1.72 billion CNY on the same day[18] - Pop Mart (9992.HK) recorded a trading volume of 13.05 billion CNY with a net buy of 2.08 billion CNY[18]

港股通50ETF（159712）领涨超1.2%，科技消费板块获资金关注。 国泰海通指出，科技制造板块中，电子行业获外资和融资资金显著流入，机械设备则出现明显流 出；TMT板块表现活跃，传媒行业外资小幅流入，计算机和通信行业融资资金流入居前。消费板块整 体承压，食品饮料行业外资持续流出，但ETF资金逆势流入。从全球资金流向看，外资边际流入新兴市 场，中国和韩国市场获外资增配，港股市场外资流入规模居前。 注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅及历史表现仅供分析参考，不 预示未来表现。市场观点随市场环境变化而变动，不构成任何投资建议或承诺。文中提及指数仅供参 考，不构成任何投资建议，也不构成对基金业绩的预测和保证。如需购买相关基金产品，请选择与风险 等级相匹配的产品。基金有风险，投资需谨慎。 每日经济新闻 （责任编辑：董萍萍 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 港股通50E ...